SINGAPORE, Dec. 17, 2012 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces the launch of NuQ®, its range of research use only epigenetic immunoassays, to be available for sale at www.nucleosomics.com. The NuQ®products were launched at the Biochemical Society's Annual Symposium, "Epigenetic mechanisms in development and disease," held last week in Leeds, England.
The NuQ® range of products is based on the Nucleosomics® platform, which identifies and measures nucleosome structures in cell culture, serum, plasma or other biofluids. The initial range comprises 15 immunoassays across four families, each of which captures intact nucleosomes and labels a specific feature:
- NuQ®-A: a family of Adduct Kits
- NuQ®-M: a family of Histone Modification Kits
- NuQ®-V: a family of Histone Variant Kits
- NuQ®-X: a family of DNA Methylation Kits
A list of products in each family of tests is available on Volition's product website www.nucleosomics.com.
Dr. Jake Micallef, Chief Scientific Officer for Volition's Nucleosomics® platform, says: "These kits, which we are developing for clinical use in oncology, can also be used by a wide range of other researchers to study epigenetic structures in nucleosomes. The patent-protected technology is a novel and basic epigenetic tool applicable to researchers working in many disease areas as well as diverse biological fields like apoptosis, embryology, and stem cell research. Our range of NuQ kits will address these varied needs."
Thomas Bygott, Volition's Director of Sales & Marketing, says: "Our proprietary kits will be €799-999 (approx. US$1050-$1300). We estimate that the addressable market for these assays is several thousand kits per year. Epigenetics is one of the fastest growing disciplines in the life sciences, as scientists realize the potential of epigenetics to revolutionize our understanding of cellular processes. Our products uniquely profile intact nucleosomes enabling quantification of, and comparison between, various epigenetic features. They are incredibly simple, reliable, robust, and reproducible, and no special equipment or training is needed beyond those required for standard ELISA tests."
VolitionRX's development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.
You can find more information about VolitionRX at our website at www.volitionrx.com, on Twitter at www.twitter.com/VolitionRX, LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.
Safe Harbor Statement
Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE VolitionRx Limited